Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

Cytotoxic T lymphocyte trafficking and survival in an augmented fibrin matrix carrier.

Zou Z, Denny E, Brown CE, Jensen MC, Li G, Fujii T, Neman J, Jandial R, Chen M.

PLoS One. 2012;7(4):e34652. doi: 10.1371/journal.pone.0034652. Epub 2012 Apr 4.

2.

HLA Tetramer Based Artificial Antigen-Presenting Cells Efficiently Stimulate CTLs Specific for Malignant Glioma.

Jiang X, Lu X, Liu R, Zhang F, Zhao H.

Clin Cancer Res. 2007 Dec 15;13(24):7329-34.

3.

Killing effect of interleukin-13 receptor alpha 2 (IL-13Ralpha2) sensitized DC-CTL cells on human glioblastoma U251 cells.

Yan X, Su Z, Zhang J, Wu Z, Ye S, Lu X, Wu J, Zeng Y, Zheng W.

Cell Immunol. 2010;263(2):172-5. doi: 10.1016/j.cellimm.2010.03.013. Epub 2010 Mar 27.

PMID:
20400066
4.

Interleukin 15 promotes antigen-independent in vitro expansion and long-term survival of antitumor cytotoxic T lymphocytes.

Lu J, Giuntoli RL 2nd, Omiya R, Kobayashi H, Kennedy R, Celis E.

Clin Cancer Res. 2002 Dec;8(12):3877-84.

5.
6.
7.

Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take.

Kruse CA, Lillehei KO, Mitchell DH, Kleinschmidt-DeMasters B, Bellgrau D.

Proc Natl Acad Sci U S A. 1990 Dec;87(24):9577-81.

8.

IL-15 induces unspecific effector functions in human peptide-specific CD8+ T-cell cultures.

Lyngstrand ST, Würtzen PA, Ødum N, Nissen MH, Röpke C.

Scand J Immunol. 2002 Dec;56(6):602-10.

9.

Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells.

Brown CE, Vishwanath RP, Aguilar B, Starr R, Najbauer J, Aboody KS, Jensen MC.

J Immunol. 2007 Sep 1;179(5):3332-41.

10.

Role of 4-1BB (CD137) in the functional activation of cord blood CD28(-)CD8(+) T cells.

Kim YJ, Brutkiewicz RR, Broxmeyer HE.

Blood. 2002 Nov 1;100(9):3253-60.

11.

Tumor mRNA-loaded dendritic cells elicit tumor-specific CD8(+) cytotoxic T cells in patients with malignant glioma.

Kobayashi T, Yamanaka R, Homma J, Tsuchiya N, Yajima N, Yoshida S, Tanaka R.

Cancer Immunol Immunother. 2003 Oct;52(10):632-7. Epub 2003 Jun 21.

PMID:
12827308
12.

Interleukin 7 can enhance antigen-specific cytotoxic-T-lymphocyte and/or Th2-type immune responses in vivo.

Sin JI, Kim J, Pachuk C, Weiner DB.

Clin Diagn Lab Immunol. 2000 Sep;7(5):751-8. Erratum in: Clin Diagn Lab Immunol 2000 Nov;7(6):991. Patchuk C [corrected to Pachuk C].

13.

Cervical cancer cells induce apoptosis of cytotoxic T lymphocytes.

Contreras DN, Krammer PH, Potkul RK, Bu P, Rossi JL, Kaufmann AM, Gissmann L, Qiao L.

J Immunother. 2000 Jan;23(1):67-74.

PMID:
10687139
14.
15.

Immunoregulatory effects of interleukin 2 and interferon on syngeneic murine malignant glioma-specific cytotoxic T-lymphocytes.

Yamasaki T, Kikuchi H, Yamashita J, Handa H, Kuwata S, Taguchi M, Namba Y, Hanaoka M.

Cancer Res. 1988 Jun 1;48(11):2981-7.

17.

Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs.

Frankenberger B, Pohla H, Noessner E, Willimsky G, Papier B, Pezzutto A, Kopp J, Oberneder R, Blankenstein T, Schendel DJ.

Clin Cancer Res. 2005 Mar 1;11(5):1733-42.

18.

Interleukin 2-activated cytotoxic lymphocytes in cancer therapy.

Grimm EA, Jacobs SK, Lanza LA, Melin G, Roth JA, Wilson DJ.

Symp Fundam Cancer Res. 1986;38:209-19.

PMID:
3489259
19.

Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.

Kemp RA, Ronchese F.

J Immunol. 2001 Dec 1;167(11):6497-502.

20.

Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.

Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC.

Cancer Res. 2004 Dec 15;64(24):9160-6.

Supplemental Content

Support Center